A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs Fludarabine (Primary) ; Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 04 Apr 2019 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 12 Jun 2018 Planned End Date changed from 30 Mar 2027 to 31 Dec 2030.